We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Saliva-Based Testing to Enable Early Detection of Cancer, Heart Disease or Parkinson’s

By LabMedica International staff writers
Posted on 27 Jun 2025

Saliva is one of the most accessible biological fluids, yet it remains underutilized in clinical practice. More...

While saliva samples are used to perform genetic tests to determine, for example, paternity, the potential of saliva-based clinical analysis goes far beyond this, as shown in new research published in npj Genomic Medicine.

A research team at the University of the Basque Country (UPV/EHU, Biscay, Spain) analyzed saliva samples from more than 350 people and catalogued the common variations in DNA, known as genetic polymorphisms, or SNPs (single-nucleotide polymorphisms), that could influence genome function in saliva. Specifically, they found that these polymorphisms act as a switch that activates or deactivates the function of the genes they affect. Comparing the data from their study with the results of previous large international genetic studies on the risk of developing chronic diseases, they observed that many of the same polymorphisms that were detected in the saliva are associated with a higher risk of developing common diseases such as prostate cancer, coronary disease, Parkinson’s and Type 2 diabetes.

Furthermore, using advanced statistical tools, the research group demonstrated that these markers can explain a significant proportion of the genetic heritability of various diseases, in some cases with greater precision than traditional blood indicators. Although these findings need to be validated in larger cohorts for each of the diseases, they represent a significant advance in identifying non-invasive disease biomarkers. This work opens the door to developing saliva-based testing that could, in the future, be used for the early detection of diseases or for monitoring treatments, without the need to extract blood or perform other invasive procedures. Another contribution from this study is the creation of the largest public database of genetic data derived from saliva samples, which can be consulted via an open-access platform. The open-access nature of the database is expected to encourage new research studies and innovations in different biomedical disciplines.

“Our results show that molecular markers present in saliva can reflect systemic pathological processes beyond the oral cavity,” said José Ramón Bilbao, Professor of Medical Genetics at the EHU and one of the lead authors of the study.

Related Links:
UPV/EHU


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.